Co-Diagnostics, Inc. (CODX)
NASDAQ: CODX · Real-Time Price · USD
1.875
-0.165 (-8.09%)
Jul 28, 2026, 10:59 AM EDT - Market open
Co-Diagnostics Revenue
Co-Diagnostics had revenue of $145.95K in the quarter ending March 31, 2026, with 190.30% growth. This brings the company's revenue in the last twelve months to $718.17K, down -79.47% year-over-year. In the year 2025, Co-Diagnostics had annual revenue of $622.49K, down -84.10%.
Revenue (ttm)
$718.17K
Revenue Growth
-79.47%
P/S Ratio
10.39
Revenue / Employee
$6,245
Employees
115
Market Cap
6.86M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 622.49K | -3.29M | -84.10% |
| Dec 31, 2024 | 3.92M | -2.90M | -42.53% |
| Dec 31, 2023 | 6.81M | -27.41M | -80.09% |
| Dec 31, 2022 | 34.22M | -63.67M | -65.04% |
| Dec 31, 2021 | 97.89M | 23.33M | 31.30% |
| Dec 31, 2020 | 74.55M | 74.34M | 34,579.90% |
| Dec 31, 2019 | 214.97K | 175.06K | 438.63% |
| Dec 31, 2018 | 39.91K | 32.25K | 420.90% |
| Dec 31, 2017 | 7.66K | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 10.00K | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Trinity Biotech | 43.79M |
| Vivos Therapeutics | 19.57M |
| Picard Medical | 5.47M |
| IceCure Medical | 3.57M |
| VolitionRx | 2.47M |
| Sintx Technologies | 1.03M |
| Nexalin Technology | 275.58K |
| Phaos Technology Holdings (Cayman) Limited | 147.64K |
CODX News
- 3 hours ago - Co-Diagnostics joint venture CoSara provides ebola test kits for India studies - TheFly
- 3 hours ago - Co-Diagnostics Joint Venture CoSara Provides Ebola Test Kits for Analytical Studies - PRNewsWire
- 6 days ago - Co-Diagnostics Joint Venture CoSara Initiates Clinical Studies in India for Tuberculosis Test on PCR Platform - PRNewsWire
- 7 days ago - Co-Diagnostics Proxy statement: Proxy filing - Filings
- 12 days ago - Co-Diagnostics appoints Wes Lindsey as Chief Scientific Officer - TheFly
- 12 days ago - Co-Diagnostics Appoints Wes Lindsey, PhD, MBA as Chief Scientific Officer - PRNewsWire
- 18 days ago - Co-Diagnostics Proxy statement: Proxy filing - Filings
- 20 days ago - Co-Diagnostics Invited to Participate in NPOC Tuberculosis Diagnostics Workshop in Bangkok, Thailand - PRNewsWire